Dr. Caskey’s work focuses on the development and clinical evaluation of novel immunotherapeutic strategies against infectious diseases, with a special emphasis on HIV. Caskey has led a series of early-phase clinical studies to evaluate the safety and efficacy of broadly neutralizing anti-HIV antibodies, now considered one of the most promising strategies to achieve HIV remission, as well as potential alternatives to antiretrovirals for both therapy and prevention. Dr. Caskey graduated from medical school at the Federal University of Sergipe in Brazil. She then completed an internal medicine residency at Saint Luke’s Roosevelt Hospital, in New York, followed by fellowship training in infectious diseases at New York Presbyterian-Weill Cornell Medical Center. Dr. Caskey is an attending physician in infectious diseases at Weill Cornell Medicine Center and an elected member of the American Society of Clinical Investigation.
At the completion of this educational session, participants will:
1. Know about new anti-HIV broadly neutralizing antibodies in clinical development.
2. Understand results from two prevention efficacy studies (AMP trials) with VRC01, an HIV bNAb.
3. Be aware of recent clinical trials of engineered HIV bNAbs.
4. Know about new delivery systems of HIV bNAbs that are entering clinical evaluation.
This CME activity has approved for
AMA PRA Category 1 Credit™ for May 12, 2021 as a live activity. This activity will also be available as an enduring activity from May 13, 2021, through May 11, 2024.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. Braun (Planner/Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Marina Caskey (Presenter) has no relevant financial relationships to disclose. Dr. Caskey will support her presentation and clinical recommendations with the best available evidence from the medical literature and will submit her slides in advance for adequate peer review.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Click here to take the CME Evaluation and Post-Meeting Evaluation
Download Article PDF/Slides